Feeds:
Posts
Comments

Posts Tagged ‘Genentech’

Is Eli Lilly the “mystery suitor” for ImClone? – Eli Lilly & Co. is in advanced talks to buy cancer-drug developer ImClone Systems for $70 a share, or $6.1 billion, The Wall Street Journal reported on Thursday, citing people familiar with the matter…more And why the big interest in ImClone? Business Week says “it’s the pipeline.”

Prasugrel delayed…again – Once again, the FDA has delayed its approval of prasugrel, a blood thinner that Lilly and its partner, Daiichi Sankyo, have been hoping will one day compete against Plavix, which is marketed by Bristol-Myers Squibb and Sanofi-Aventis…more

Judge: Amgen yes, Roche no – A federal judge in Boston ruled the drugmaker infringed on Amgen’s patents with its Mircera anemia med, essentially upholding a preliminary decision issued in February. The order by US District Court Judge William Young deals a big setback to Roche, which already cut costs after its plans to market Mircera flopped…more

Credit crunch? Roche says, nah…we still want Genentech – The market isn’t so sure Roche can raise the money to buy Genentech, but Roche seems pretty confident…more

Encouraging data for Pfizer’s HIV drug – The Pfizer Inc. AIDS drug maraviroc helps thwart the HIV virus in nearly half of people who have developed resistance to other treatments, according to two related studies published on Wednesday…more

Pfizer bailing out of some therapeutic areas for drug development – Pfizer Inc  will drop efforts to develop medicines for heart disease, as part of a reshuffling of its research activities that the pharmaceutical giant plans to announce on Tuesday, according to a Wall Street Journal report. Pfizer also is expected to announce it will abandon therapies for obesity and bone health to focus on more lucrative areas such as cancer and Alzheimer’s disease, WSJ said on its online site…more More here from Forbes

The Pfizer pipeline: current status – Even as Pfizer is bailing out of drug research for heart disease, the company’s late-stage pipeline has increased to 25 projects from 16 in the past six months…more

A potential Viagra competitor derived from a plant with…well, a pretty bizarre name!

Merck drops experimental weight-loss pill – The drugmaker made the decision after spending months reviewing trials showing the taranabant obesity pill caused psychiatric side effects. You may recall that a late-stage trial showed the drug didn’t yield the hoped-for weight loss of 5 percent at the 2 mg dose the drugmaker hoped to sell…more

Daiichi Sankyo cleared to buy Indian drugmaker Ranbaxy.

From PharmExecspecialty drug prices spiking.

Big settlement by Cephalon on out-of-bounds marketing practices. Whistleblower vindicated.

What’s $1.2 billion between competitors? Ask Boston Scientific

Reblog this post [with Zemanta]

Read Full Post »

The Sales Force Shuffle, from Pharmaceutical Executive – The last week the pharma atmosphere was abuzz with news about sales force cuts, outsourcing, and overhauls. First, Schering-Plough announced that it had eliminated the 1,000 sales positions it said it would trim in April. This is being done as part of a new sales model called—internally—a productivity transformation program (PTP). The new model, to go into effect next month, will streamline the sales force to take a more customer-centric approach, including targeted and relevant physician calls and a relationship management–oriented business model…more

Alpharma to King: No. – In a filing with the Securities and Exchange Commission, Alpharma calls the $37-a-share offer was inadequate and continues to explore all strategic alternatives, including a possible sale to King or another party for a higher price…more

Lilly CEO to Boston: you’re scaring us away – The ink is barely dry on a new law governing how drugmakers can market to docs, but Lilly’s John Lechleiter isn’t wasting time trying to make lawmakers regret their decision. In remarks to the Associated Industries of Massachusetts Executive Forum, he claims the law will hamper innovation and force companies to reconsider expanding in Massachusetts, The Boston Business Journal reports…more

B-I goes to the shrink – The drugmaker has ended a contract with InVentiv, one of the players in the Rent-A-Rep business, which was promoting its troubled Micardis, an angiotensin receptor blocker, otherwise known as a blood pressure med…more

The needle or the drug? – Acupuncture works as well as Wyeth’s antidepressant to fight hot flashes and other menopausal symptoms caused by breast cancer treatment, and its benefits last longer without causing unwanted side effects, according to new research…more

Pfizer’s Pfuture – The big drugmaker is dramatically stepping up sales efforts in emerging markets, overhauling US business operations and slashing more costs ahead of the 2011 patent loss for cholesterol blockbuster Lipitor, the Associated Press informs us…more Plus, going after emerging markets for growth

Paxil damages sperm? – A group of 35 healthy men who were given Paxil over a five-week period had higher levels of sperm with damaged DNA, according to a report..more

Medicis to re-state numbers; stock plunges.

Tarceva linked to liver damage – Genentech Inc and OSI Pharmaceuticals have alerted doctors about cases of liver damage among patients who took the cancer drug Tarceva in a post-approval study, U.S. regulators said on Tuesday…more

Takeda goes for diabetes combo – Takeda Pharmaceutical Co said on Wednesday it had applied for approval to market in the United States the SYR-322 and the Actos diabetes drugs in a single tablet for the treatment of type 2 diabetes…more

An interesting analysis on adverse event reporting, and social media.

Is the war on cancer really winnable? A realistic and pessimistic analysis from Newsweek.

Reblog this post [with Zemanta]

Read Full Post »

The connection between high cholesterol and risk of stroke is questioned.

Is Avandia contributing to bone breakage? And more bad news for the GSK diabetes treatment…two healthcare providers drop the medication from their formularies. For switcheroos, it appears that most doctors are leaning toward Januvia or Byetta.

Long-ish article from Business Week on Genentech‘s current and future status. And, here is one doctor’s summary about why he voted “nay” on the FDA panel considering Avastin for breast cancer.

Novartis has plans for 4 more cancer drugs.

Certain lymphoma drugs may be derailed based on this Medicare decision.

Teva‘s Copaxone may actually cut the risk of developing MS.

An interesting perspective from Derek Lowe on why it’s not all bad that companies developing competing drugs in the same class.

An update on the status of eDetailing.

Here’s a fascinating finding – does body temperature (specifically, a fever) unlock the effects of autism??

Read Full Post »

« Newer Posts